Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
WuXi Biologics
Sort By
Newest First
1 / 3
Commitment to ESG Principles
How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?
Pharma's Almanac
PAO-03-24-CL-03
Mar 08, 2024
Accelerating Product Development
What strategies are being employed to accelerate product development and commercialization without compromising quality?
Pharma's Almanac
PAO-03-24-CL-02
Mar 08, 2024
Unmet Needs
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
Pharma's Almanac
PAO-06-022--RT-01
Jun 24, 2022
Industry Challenges
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Pharma's Almanac
O-06-022--RT-01
Jun 24, 2022
Leadership
Q: What’s the key to being a leader in the industry?
Pharma's Almanac
PAO-03-022-RT-02
Mar 11, 2022
Milestones
Q: What important company milestone do you anticipate reaching in 2022?
Pharma's Almanac
PAO-03-022-RT-01
Mar 11, 2022
Facility
WuXi Biologics Completes Weather-Tight Seal of its Biologics Manufacturing Facility in Ireland
WuXi Biologics
PR-M03-20-NI-019
Mar 12, 2020
Coronavirus
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19
WuXi Biologics
PR-M02-20-NI-033
Feb 25, 2020
Clinical Results
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321
WuXi Biologics
PR-M02-20-NI-032
Feb 24, 2020
Coronavirus
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
WuXi Biologics
PR-M01-20-NI-041
Jan 29, 2020
M&A
Wuxi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
WuXi Biologics
PR-M01-20-NI-025
Jan 16, 2020
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
WuXi Biologics
PA1806
Jan 09, 2020
Drug Development
WuXi Biologics Congratulates Tychan on the World’s First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers
WuXi Biologics
PR-M11-19-NI-018
Nov 19, 2019
Expansion
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing
WuXi Biologics
PR-M06-19-NI-054
Jun 27, 2019
Vaccine
WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract
WuXi Biologics
PR-M05-19-NI-070
May 24, 2019
Strategic Partnership
I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs
WuXi Biologics
PR-M04-19-NI-065
Apr 19, 2019
GMP
WuXi Biologics Receives EMA GMP Certificates
WuXi Biologics
PR-M03-19-NI-061
Mar 22, 2019
Finance
WuXi Biologics Continues to Deliver Record Results
WuXi Biologics
PR-M03-19-NI-052
Mar 19, 2019
Immuno-Oncology
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million
WuXi Biologics
PR-M02-19-NI-067
Feb 28, 2019
Strategic Collaborations
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million
WuXi Biologics
PR-M12-18-NI-053
Dec 17, 2018
1 / 3
